Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Deffered Revenue: 2011-2025

Historic Non-Current Deffered Revenue for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $2.7 million.

  • Niagen Bioscience's Non-Current Deffered Revenue rose 3.68% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 3.68%. This contributed to the annual value of $2.6 million for FY2024, which is 22.11% down from last year.
  • Per Niagen Bioscience's latest filing, its Non-Current Deffered Revenue stood at $2.7 million for Q3 2025, which was down 0.00% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Non-Current Deffered Revenue registered a high of $4.4 million during Q2 2021, and its lowest value of $2.6 million during Q3 2024.
  • For the 3-year period, Niagen Bioscience's Non-Current Deffered Revenue averaged around $3.1 million, with its median value being $3.3 million (2024).
  • In the last 5 years, Niagen Bioscience's Non-Current Deffered Revenue increased by 16.26% in 2021 and then slumped by 32.24% in 2024.
  • Over the past 5 years, Niagen Bioscience's Non-Current Deffered Revenue (Quarterly) stood at $4.3 million in 2021, then fell by 7.96% to $4.0 million in 2022, then decreased by 17.23% to $3.3 million in 2023, then fell by 22.11% to $2.6 million in 2024, then climbed by 3.68% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.7 million for Q2 2025, and $2.6 million during Q1 2025.